Evidence map›Paper›PMID 18658134›Full record

ArticleThe Journal of biological chemistry2008

Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation.

Erin M Conn, Mark A Madsen, Benjamin F Cravatt, Wolfram Ruf, Elena I Deryugina, James P Quigley

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Neurotheranostics as personalized medicines.Advanced drug delivery reviews · 2019
    Review
  8. Article
  9. Tumor cell intravasation.American journal of physiology. Cell physiology · 2016
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Erin M ConnDepartments of Cell Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Mark A Madsen
Benjamin F Cravatt
Wolfram Ruf
Elena I Deryugina
James P Quigley
University of California, San Diego · USScripps Research Institute · US

Funding

Transmembrane Proteins Involved in Human Tumor ExpansionR01CA105412 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI QUIGLEY, JAMES P · 2004 to 2020
$5.8M
MATRIX METALLOPROTEASES IN TUMOR CELLSR01CA055852 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI QUIGLEY, JAMES P · 1992 to 2009
$2.9M
MOLECULAR PATHOLOGY OF CANCER TRAINING GRANTT32CA077109 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KAMPS, MARK P · 1998 to 2009
$1.2M
NCI NIH HHS 2 T32CA77109-08NCI NIH HHS CA105412NCI NIH HHS CA55852NCI NIH HHS R01 CA055852NCI NIH HHS R01 CA105412NCI NIH HHS T32 CA077109
6 · The paper itself

Abstract

In order to better understand the molecular and cellular determinants of tumor cell intravasation, our laboratory has generated a pair of congenic human HT-1080 fibrosarcoma variants (i.e. HT-hi/diss and HT-lo/diss) differing 50-100-fold in their ability to intravasate and disseminate. To investigate the molecular differences underlying the distinct dissemination capacities of these HT-1080 variants, we performed a comparative analysis of the cell surface proteomes of HT-hi/diss and HT-lo/diss. Cell membrane proteins were enriched by biotinylation and avidin precipitation and analyzed by tandem mass spectrometry employing multidimensional protein identification technology. By this approach, 47 cell surface-associated molecules were identified as differentially expressed between the HT-1080 intravasation variants. From these candidates, four targets (i.e. TIMP-2, NCAM-1, JAM-C, and tissue factor (TF)) were selected for further biochemical validation and in vivo functional verification. Western blot analysis of the cell surface enriched fractions confirmed the proteomic array data, demonstrating that, in vitro, TIMP-2 protein was increased in the HT-lo/diss variant, whereas NCAM-1, JAM-C, and TF levels were increased in the HT-hi/diss variant. Corresponding in vivo differences in levels of TIMP-2, JAM-C, and TF were demonstrated in primary tumors grown in the chick embryo. Finally, functional inhibition of one selected protein (i.e. TF) by small interfering RNA silencing or ligation with a function-blocking antibody significantly reduced HT-hi/diss intravasation, thus clearly implicating TF in the early steps of tumor cell dissemination. Overall, our cell surface proteomic analysis provides a powerful tool for identification of specific cell membrane molecules that contribute functionally to intravasation and metastasis in vivo.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCell Adhesion MoleculesCell Line, TumorChick EmbryoFibrosarcomaGene SilencingHumansNeoplasm InvasivenessNeoplasm MetastasisNeoplasm ProteinsProteomicsRNA, Small InterferingCell Adhesion MoleculesNeoplasm ProteinsRNA, Small Interfering

Identifiers

PMID18658134
PMCPMC2546538
OpenAlexW2102419220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.